The growing demand for alopecia treatments is mainly driven by the rising global prevalence of alopecia, influenced by ...

In the worst-case scenario, an unfavourable judgment would prevent Sun Pharma from launching Leqselvi until the patent expires, delaying its market entry.

According to Citi, the delay in the launch of Sun Pharma's alopecia areata drug, Leqselvi, could impact its near-term ...

This decision delays Sun Pharma's planned US launch of the product, which could be deferred for several months if the company ...

Despite winning an alopecia areata approval for its drug Leqselvi in July, Sun Pharma will have to wait a while longer to ...

Pharma giant, Sun Pharmaceutical's launch of its specialty drug Leqselvi in the U.S. market is in limbo as the U.S. District Court in New Jersey has issued a preliminary injunction.

Sun Pharmaceutical Industries: The US District Court of New Jersey has granted a preliminary injunction delaying the launch ...

Incyte filed a lawsuit to try to block the launch of Leqselvi, claiming that the drug infringed a US patent (No. 9,662,335) ...

Shares of Sun Pharmaceutical fell 2.64 per cent after the pharma major recently announced that the US District Court of delayed the launch of its new drug - Leqselvi.

The second loser today was NTPC, which operates in the Power - Generation/Distribution sector and is classified as a large ...

Thirty out of the 41 analysts tracking the company have a 'buy' rating on the stock, seven suggest a 'hold' and four have a ...

Sun Pharmaceutical Industries slipped 4.30% to 1,778.85 after the US District Court of New Jersey has decided to grant a preliminary injunction delaying the launch of Leqselvi (Baldness treatment) in ...